The Brazilian Health Regulatory Agency has successfully completed ANVISA inspection at Concord Biotech’s API manufacturing facility in Limbasi. The inspection took place from June 8, 2026 to June 12, 2026.
The successful completion of the ANVISA inspection marks a significant milestone in Concord Biotech’s global growth journey. This achievement reinforces the company’s commitment to the highest standards of quality and regulatory excellence while strengthening its global manufacturing and regulatory footprint. It also advances its international expansion strategy by enhancing access to one of the world’s largest pharmaceutical markets and broadening the reach of its high-quality APIs across key global geographies.
Concord Biotech is an India-based biopharma company and one of the leading global developers and manufacturers of select fermentation-based APIs across Immunosuppressants and oncology.
